2011

Lipitor Won't Go Gentle Into that Good Generic Night. Pfizer is taking a number of steps to protect it's Lipitor franchise and it hopes that many patients currently taking Lipitor will remain loyal to the brand.

Social media occupied a good deal of our attention in 2010 and many of the pharma people Pharmaguy met and interacted with in 2010 are involved in social media campaigns in one way or another.

If pharma marketers are going to be successful engaging consumers (mostly women) via social media, then they need to be more sensitive about how they portray women in ads and very savvy about how they handle comments (if they allow comments).

Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.

Self Care Catalysts' Patient Intelligence Insights Guide™ on Diabetes is the only integrated patient-and consumer-centric report that explores how people suffering from an invisible condition such as diabetes actually circumnavigate their health condition, using the unique Self Care Health Decision Making Dynamics framework™. It is an example of what Grace Soyao, Founder & Chief Strategy Officer of Self Care Catalysts Inc., a health research and strategy company, means by 'Finding the Consumer within the Patient.'

From the Audition in the Press to TV, Web, and Print Advertising. Pfizer and Amgen demonstrate how to launch a branded spokesperson campaign starting from a bit of over-the-top unregulated press relations to fully regulated TV, print, and Web advertising. It must be costing a mint!

Opening the Door to FDA-Compliant Branded Tweets: Deck.ly has enormous potential for pharmaceutical marketers who have been chaffing at the bit to post meaningful branded messages via Twitter but who have been stymied by lack of guidance from FDA regarding how to provide fair balance within the 140-character limit of Twitter.

Welcome to Volume 10, Issue #14 (22 SEPTEMBER 2011) of Pharma Marketing News.

Welcome to Volume 10, Issue No. 1 (Jan 12, 2011) of Pharma Marketing News. This issue of Pharma Marketing News is devoted to the Pharma Marketing Yearbook (PMY), which is a commemorative record of pharmaceutical marketing issues and highlights of the past year.

When asked what the # 1 concern pharmaceutical marketers have regarding using social media, the adverse event reporting (AER) boogey man is cited most often. The urge to avoid this boogey man at all costs may have more to do with CEO compensation that with fears of rank-an-file marketers.